Subscribe
White Paper

Genomics Innovation

Health Care In The Genomic Age

Over the last five years, we have passed key inflection points in the ability to access, manipulate, and understand the molecular building blocks of the human body. The “genomic age” of medicine promises profound ramifications for human health and for the companies involved, among them: (i) tool providers that enable basic research, sharpen the precision of diagnostics, and guide personalized medicine; (ii) diagnostic platforms deploying data that informs the treatment of disease; (iii) and other companies deploying technology and data to create next-generation treatments and cures, increasing returns on therapeutic research and development for the first time in 20 years.

ARK Invest estimates that by 2024 therapeutic pipelines and tool providers should generate hundreds of billions of dollars in new revenue and trillions in new market capitalizations as they transition to the genomic age.

Download ARK’s white paper to learn more about the “Genomic Age” and its potential impact on listed equity markets.